VRDN
Viridian Therapeutics Inc
20.70$
-3.6%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -51.2% | -271.8% | -216.7% | -703.6% | -320.1% | -808.2% | -2,836.1% | -1,842.1% | -5,295.6% | -58,652.9% | -76,926.8% | -390.1% | |
| 3.3% | 7.2% | 5.7% | 7.7% | 3.4% | 6.5% | 22.8% | 4.0% | 14.4% | 166.2% | 178.8% | -9.5% | |
| 99.5% | 118.8% | 63.3% | 60.2% | 43.9% | 89.0% | 347.1% | 488.2% | 1,115.4% | 21,392.4% | 13,957.0% | 62.5% | |
| – | – | 19.2% | 62.5% | 43.4% | 86.9% | 7,237.0% | 743.9% | 1,115.4% | – | – | – | |
| 2.4% | 43.3% | 65.4% | -111.6% | 23.1% | 37.0% | 421.6% | 58.2% | 900.8% | -3,001.6% | 3,178.1% | 32.5% | |
| 6.2% | 4.8% | 0.1% | 6.1% | 5.3% | 1.9% | 4.0% | 11.4% | 45.0% | 286.0% | 169.2% | 0.7% | |
| -6.3% | -3.7% | -0.1% | 25.8% | -356.6% | 632.7% | -4,807.7% | -2,507.3% | -6,497.0% | -30,016.6% | -75,712.3% | -53.0% | |
| – | – | – | – | – | – | 4.2% | – | – | 4,613.4% | – | – | |
| – | -14.3% | -5.2% | -30.4% | -35.2% | – | -4.2% | 4,228.0% | 10.3% | 184.7% | – | 1.6% | |
| – | – | -10.0% | 133.2% | -27.8% | -52.3% | -815.9% | 168.7% | 257.0% | 4,777.1% | 0.0% | 40.8% | |
| 171.2% | 500.6% | -7.7% | 1,310.8% | 499.8% | 1.6% | 9,648.7% | 4,228.0% | 18,185.3% | 71,869.4% | 151,568.5% | 602.3% | |
| 113.7% | 225.1% | -224.5% | 633.0% | -176.9% | -174.0% | 2,004.9% | -121.4% | 6,392.8% | -16,800.0% | -1,070.5% | 159.2% | |
| -57.4% | -276.6% | -216.8% | -709.8% | -325.4% | -810.1% | -2,840.1% | -1,853.5% | -5,340.6% | -58,938.9% | -77,096.0% | -390.8% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.